ID   K562/AS2
AC   CVCL_4V85
DR   Wikidata; Q54899406
RX   CelloPub=CLPUB00269;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; As2O3).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 29-06-23; Version: 14
//
RX   CelloPub=CLPUB00269;
RA   Zhuo J.-C., Wang M.-C., Tao X.-M., Li M., Nie L.-P., Zhang Q.-L.,
RA   Shi D.-Y.;
RT   "Establishment of arsenic trioxide-resistant K562/AS2 cell line and
RT   the mechanism of multidrug resistance.";
RL   Chin. J. Pathophysiol. 18:840-843(2002).
//